Psychiatry and Neurology, Neurology · Amherst, NY
NPI
1316155500
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
3980a Sheridan Dr
Amherst, NY, 14226
Phone (716) 250-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$8.7M
423,172 services
Medicare patients, 2024
1,229
Average age 72
Drug cost, 2024
$366K
5,439 prescriptions
Company payments, 2025
$32K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bela Ajtai was code J0174 (injection, lecanemab-irmb, 1 mg), 81,000 times for 12 patients. In total Bela Ajtai billed 423,172 services in 103 codes, and Medicare paid $8.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0174 Injection, lecanemab-irmb, 1 mg | Office | 81,000 | 12 | $1.05 | $85K |
| J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 44,180 | 34 | $38.54 | $1.7M |
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 35,107 | 25 | $16.44 | $577K |
| J2350 Injection, ocrelizumab, 1 mg | Office | 25,203 | 26 | $42.14 | $1.1M |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 15,000 | 12 | $0.87 | $13K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 11,740 | 34 | $24.52 | $288K |
| J3032 Injection, eptinezumab-jjmr, 1 mg | Office | 10,100 | 21 | $13.38 | $135K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 7,879 | 54 | $0.22 | $1,739 |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 6,625 | 11 | $33.79 | $224K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 1,314 | 243 | $0.49 | $645 |
| J0897 Injection, denosumab, 1 mg | Office | 1,141 | 13 | $19.94 | $23K |
| A9578 Injection, gadobenate dimeglumine (multihance multipack), per ml | Office | 1,139 | 128 | $1.31 | $1,495 |
| 96366 Intravenous Infusion, Hydration | Office | 1,137 | 42 | $15.35 | $17K |
| 96365 Intravenous Infusion, Hydration | Office | 894 | 139 | $45.51 | $41K |
| 96413 Chemotherapy Administration | Office | 879 | 168 | $91.80 | $81K |
By year: 2022 $6.7M for 272,852 services; 2023 $6.9M for 296,645 services; 2024 $8.7M for 423,172 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 13 | 13 | $5.88 | $76.44 |
Medicare prescription drug claims, 2024
In 2024, the drug Bela Ajtai prescribed most often to Medicare patients was Donepezil Hcl, with 1,437 prescriptions and refills. In total Bela Ajtai wrote 5,439 Medicare prescriptions that cost $366K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Donepezil Hcl Generic | 1,437 | 2,809 | 455 | $16K |
| Memantine Hcl Generic | 1,083 | 2,110 | 332 | $32K |
| Sertraline Hcl Generic | 622 | 1,273 | 216 | $8,034 |
| Galantamine Er Galantamine Hbr | 558 | 1,044 | 180 | $51K |
| Memantine Hcl Er Memantine Hcl | 367 | 644 | 107 | $26K |
| Quetiapine Fumarate Generic | 224 | 381 | 84 | $2,867 |
| Trazodone Hcl Generic | 124 | 244 | 57 | $1,246 |
| Mirtazapine Generic | 114 | 190 | 36 | $2,122 |
| Levetiracetam Generic | 94 | 168 | 22 | $3,077 |
| Rivastigmine Generic | 90 | 151 | 30 | $16K |
| Carbidopa-Levodopa Carbidopa/Levodopa | 62 | 118 | 22 | $2,227 |
| Gabapentin Generic | 54 | 96 | 12 | $1,278 |
| Buspirone Hcl Generic | 53 | 93 | 16 | $597 |
| Duloxetine Hcl Generic | 52 | 104 | 12 | $1,819 |
| Escitalopram Oxalate Generic | 48 | 88 | 17 | $380 |
Brand drugs: - claims; generic drugs: 5,315 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bela Ajtai $32K ($32K in general payments such as food, travel and fees) from 11 companies. The largest payer was Lilly USA, LLC with $23K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 22 | $23K |
| Eisai Inc. 4523.T | 27 | $8,058 |
| Teva Pharmaceuticals USA, Inc. TEVA | 13 | $309 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 8 | $152 |
| Pfizer Inc. PFE | 3 | $61.37 |
| Abbvie Inc. ABBV | 2 | $51.86 |
| Amgen Inc. AMGN | 2 | $42.2 |
| Life Molecular Imaging Ltd | 2 | $35.08 |
| ACADIA Pharmaceuticals Inc ACAD | 1 | $26.65 |
| Lundbeck LLC | 1 | $25.75 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.